C3 glomerulopathy—understanding a rare complement-driven renal disease
The C3 glomerulopathies are a group of rare kidney diseases characterized by complement
dysregulation occurring in the fluid phase and in the glomerular microenvironment, which …
dysregulation occurring in the fluid phase and in the glomerular microenvironment, which …
Current understanding of the role of complement in IgA nephropathy
Complement activation has a role in the pathogenesis of IgA nephropathy, an autoimmune
disease mediated by pathogenic immune complexes consisting of galactose-deficient IgA1 …
disease mediated by pathogenic immune complexes consisting of galactose-deficient IgA1 …
KDIGO 2021 clinical practice guideline for the management of glomerular diseases
BH Rovin, SG Adler, J Barratt, F Bridoux… - Kidney …, 2021 - kidney-international.org
Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …
[HTML][HTML] Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies
A Servais, LH Noël, LT Roumenina, M Le Quintrec… - Kidney international, 2012 - Elsevier
Dense deposit disease and glomerulonephritis with isolated C3 deposits are
glomerulopathies characterized by deposits of C3 within or along the glomerular basement …
glomerulopathies characterized by deposits of C3 within or along the glomerular basement …
Mayo clinic/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN
S Sethi, M Haas, GS Markowitz… - Journal of the …, 2016 - journals.lww.com
Renal pathologists and nephrologists met on February 20, 2015 to establish an
etiology/pathogenesis-based system for classification and diagnosis of GN, with a major aim …
etiology/pathogenesis-based system for classification and diagnosis of GN, with a major aim …
Membranoproliferative glomerulonephritis—a new look at an old entity
S Sethi, FC Fervenza - New England Journal of Medicine, 2012 - Mass Medical Soc
This review discusses the causes, pathogenesis, and clinical management of
membranoproliferative glomerulonephritis, which accounts for 7 to 10% of biopsy-confirmed …
membranoproliferative glomerulonephritis, which accounts for 7 to 10% of biopsy-confirmed …
Eculizumab for dense deposit disease and C3 glomerulonephritis
Results The subjects included three patients with dense deposit disease (including one
patient with recurrent dense deposit disease in allograft) and three patients with C3 …
patient with recurrent dense deposit disease in allograft) and three patients with C3 …
The complexity and heterogeneity of monoclonal immunoglobulin–associated renal diseases
S Sethi, SV Rajkumar, VD D'Agati - Journal of the American …, 2018 - journals.lww.com
Monoclonal gammopathies are characterized by the overproduction of monoclonal Ig (MIg)
detectable in the serum or urine resulting from a clonal proliferation of plasma cells or B …
detectable in the serum or urine resulting from a clonal proliferation of plasma cells or B …
Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological …
Drusen are discussed frequently in the context of their association with age-related macular
degeneration (AMD). Some types may, however, be regarded as a normal consequence of …
degeneration (AMD). Some types may, however, be regarded as a normal consequence of …
[HTML][HTML] C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up
S Sethi, FC Fervenza, Y Zhang, L Zand, JA Vrana… - Kidney international, 2012 - Elsevier
C3 glomerulonephritis (C3GN) is a recently described disorder that typically results from
abnormalities in the alternative pathway (AP) of complement. Here, we describe the clinical …
abnormalities in the alternative pathway (AP) of complement. Here, we describe the clinical …